Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

Introduction: Immune-checkpoint inhibitors (ICIs) are transforming the modern era of cancer therapy. As new treatment options are becoming available, new patterns of disease behavior are manifesting. One such phenomenon, known as hyperprogressive disease (HPD), is a rare complication resulting in ex...

Full description

Bibliographic Details
Main Authors: Saro Kasparian, MD, Cesar Gentille, MD, Ethan Burns, MD, Eric H. Bernicker, MD
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JTO Clinical and Research Reports
Subjects:
Hyperprogressive disease
Non−small cell lung cancer
Stage IV
Pembrolizumab
Atezolizumab
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300175

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300175

Similar Items